Pinealon (Ala-Glu-Asp) is a synthetic tripeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology, the same institution responsible for Epithalon and Thymalin. As a short peptide, Pinealon readily crosses the blood-brain barrier and exerts its effects directly on neuronal nuclei, where it modulates gene expression through epigenetic mechanisms.
The Epigenetic Mechanism
Pinealon's primary mechanism involves interaction with DNA regulatory sequences in neuronal cells, modulating the expression of genes involved in neuroprotection, antioxidant defense, and cellular longevity. Unlike most peptides that act on cell surface receptors, Pinealon penetrates to the cell nucleus where it directly influences gene transcription — a mechanism that produces slower but more durable effects than receptor-mediated signaling.
Cognitive Aging and Neurodegeneration
Age-related cognitive decline is driven by multiple converging mechanisms: oxidative stress in neurons, mitochondrial dysfunction, accumulation of damaged proteins, and progressive neuroinflammation. Pinealon addresses several of these simultaneously through its epigenetic effects on antioxidant gene expression, mitochondrial biogenesis pathways, and inflammatory cytokine regulation.
Clinical Evidence
Russian clinical studies have demonstrated Pinealon's efficacy in improving cognitive function in elderly patients with age-related cognitive decline, with particular benefits in memory, attention, and processing speed. The compound has also shown neuroprotective effects in models of ischemic brain injury, suggesting applications beyond cognitive aging to acute neuroprotection.